199 related articles for article (PubMed ID: 17127232)
1. A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.
Gennatas C; Papaxoinis G; Michalaki V; Mouratidou D; Andreadis C; Tsavaris N; Pafiti A
J Chemother; 2006 Oct; 18(5):538-44. PubMed ID: 17127232
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
3. Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.
Tsavaris N; Kosmas C; Skopelitis H; Papadoniou N; Polyzos A; Zografos G; Adoniou E; Gryniatsos J; Felekouras E; Zacharakis M; Sigala F; Bacoyiannis C; Papastratis G; Papalambros E
Chemotherapy; 2007; 53(4):282-91. PubMed ID: 17496414
[TBL] [Abstract][Full Text] [Related]
4. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
Papadimitriou CA; Papakostas P; Karina M; Malettou L; Dimopoulos MA; Pentheroudakis G; Samantas E; Bamias A; Miliaras D; Basdanis G; Xiros N; Klouvas G; Bafaloukos D; Kafiri G; Papaspirou I; Pectasides D; Karanikiotis C; Economopoulos T; Efstratiou I; Korantzis I; Pisanidis N; Makatsoris T; Matsiakou F; Aravantinos G; Kalofonos HP; Fountzilas G
BMC Med; 2011 Jan; 9():10. PubMed ID: 21281463
[TBL] [Abstract][Full Text] [Related]
6. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
7. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group.
Maiello E; Gebbia V; Giuliani F; Paoletti G; Gebbia N; Cigolari S; Fortunato S; Pedicini T; Borsellino N; Lopez M; Colucci G
Ann Oncol; 2000 Aug; 11(8):1045-51. PubMed ID: 11038044
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
Giantonio BJ; Levy DE; O'dwyer PJ; Meropol NJ; Catalano PJ; Benson AB;
Ann Oncol; 2006 Sep; 17(9):1399-403. PubMed ID: 16873427
[TBL] [Abstract][Full Text] [Related]
9. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
Comella P; Crucitta E; De Vita F; De Lucia L; Farris A; Del Gaizo F; Palmeri S; Lannelli A; Mancarella S; Tafuto S; Maiorino L; Buzzi F; De Cataldis G;
Ann Oncol; 2002 Jun; 13(6):866-73. PubMed ID: 12123331
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Saltz LB; Cox JV; Blanke C; Rosen LS; Fehrenbacher L; Moore MJ; Maroun JA; Ackland SP; Locker PK; Pirotta N; Elfring GL; Miller LL
N Engl J Med; 2000 Sep; 343(13):905-14. PubMed ID: 11006366
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
Graeven U; Ridwelski K; Artandi M; Espana P; Schölmerich J; Rosales AM; Carlsson G; Borner M; Boussard B; Schmiegel W
Oncol Rep; 2005 Apr; 13(4):681-8. PubMed ID: 15756442
[TBL] [Abstract][Full Text] [Related]
12. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
[TBL] [Abstract][Full Text] [Related]
14. A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Kalofonos HP; Skarlos D; Bafaloukos D; Papakostas P; Bamias A; Janinis J; Timotheadou E; Kouvatseas G; Stavropoulos M; Economopulos T; Fountzilas G
Cancer Invest; 2003; 21(6):855-62. PubMed ID: 14735689
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
[TBL] [Abstract][Full Text] [Related]
16. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V
J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
[TBL] [Abstract][Full Text] [Related]
18. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
Falcone A; Masi G; Allegrini G; Danesi R; Pfanner E; Brunetti IM; Di Paolo A; Cupini S; Del Tacca M; Conte P
J Clin Oncol; 2002 Oct; 20(19):4006-14. PubMed ID: 12351598
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
20. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Budai B; Nagy T; Láng I; Hitre E
Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
